Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Operating Leases (2019 - 2025)

Fate Therapeutics (FATE) has disclosed Operating Leases for 7 consecutive years, with $73.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 5.86% year-over-year to $73.3 million, compared with a TTM value of $73.3 million through Dec 2025, down 5.86%, and an annual FY2025 reading of $73.3 million, down 5.86% over the prior year.
  • Operating Leases was $73.3 million for Q4 2025 at Fate Therapeutics, down from $74.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $109.2 million in Q4 2021 and bottomed at $73.3 million in Q4 2025.
  • Average Operating Leases over 5 years is $95.4 million, with a median of $99.8 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 44.26% in 2021, then decreased 20.04% in 2024.
  • Year by year, Operating Leases stood at $109.2 million in 2021, then decreased by 5.06% to $103.7 million in 2022, then dropped by 6.12% to $97.4 million in 2023, then fell by 20.04% to $77.8 million in 2024, then dropped by 5.86% to $73.3 million in 2025.
  • Business Quant data shows Operating Leases for FATE at $73.3 million in Q4 2025, $74.5 million in Q3 2025, and $75.7 million in Q2 2025.